ECSP003681A - Polymorphic salt - Google Patents
Polymorphic saltInfo
- Publication number
- ECSP003681A ECSP003681A ECSP003681A ECSP003681A EC SP003681 A ECSP003681 A EC SP003681A EC SP003681 A ECSP003681 A EC SP003681A EC SP003681 A ECSP003681 A EC SP003681A
- Authority
- EC
- Ecuador
- Prior art keywords
- polymorphic salt
- migraine
- prescribed
- medicine
- graph
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000000952 serotonin receptor agonist Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El presente invento trata de una forma polimórfica cristalina de un compuesto de fórmula (I) (gráfico), caracterizada por un diagrama de difracción de rayos X en polvo, obtenido al utilizar la radiación K-alfa del cobre(f = 0,15046 nm), que presenta picos principales a 9,28, 10,38, 11,37, 12,40, 16,84, 17,46, 17,53, 17,78, 17,98, 19,48, 20,70, 21,29, 21,45, 22,21, 22,64, 23,08, 25,20, y 25,79. El invento se refiere también a procedimientos para la preparación de dicha forma, a composiciones farmacéuticas que contienen la misma y a su uso en medicina, particularmente en el tratamiento de estados para los que se prescribe un agonista de recptores 5-HT, tales como, por ejemplo, la migraña.The present invention deals with a crystalline polymorphic form of a compound of formula (I) (graph), characterized by a powder X-ray diffraction diagram, obtained by using the copper's K-alpha radiation (f = 0,15046 nm ), which presents major peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70 , 21.29, 21.45, 22.21, 22.64, 23.08, 25.20, and 25.79. The invention also relates to processes for the preparation of said form, pharmaceutical compositions containing the same and their use in medicine, particularly in the treatment of conditions for which a 5-HT receptor agonist is prescribed, such as, by example, migraine.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UY26354A UY26354A1 (en) | 2000-09-25 | 2000-09-25 | POLYMORPHIC SALT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003681A true ECSP003681A (en) | 2002-04-23 |
Family
ID=38812230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003681 ECSP003681A (en) | 2000-09-25 | 2000-09-26 | Polymorphic salt |
Country Status (2)
| Country | Link |
|---|---|
| EC (1) | ECSP003681A (en) |
| UY (1) | UY26354A1 (en) |
-
2000
- 2000-09-25 UY UY26354A patent/UY26354A1/en not_active Application Discontinuation
- 2000-09-26 EC ECSP003681 patent/ECSP003681A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY26354A1 (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160208T4 (en) | Polymorphs of dasatinib and process for preparation thereof | |
| CU23200A3 (en) | Polymorphic salt | |
| AR029571A1 (en) | NEW BETA CRYSTALLINE FORM OF PERINDOPRIL TERBUTILAMINE SALT, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| MX2021011811A (en) | PROTACS THAT DEGRADE THE ESTROGEN RECEPTOR. | |
| AR049949A1 (en) | CRYSTALINE CHLORHYDRATE FORM OF (-) - (1R, 2R) -3- (3-DIMETHYLAMINO-1-ETIL-2-METHYLPROPIL) -PHENOL | |
| UA97478C2 (en) | Crystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| HU229358B1 (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
| AR034124A1 (en) | ALFA CRYSTAL FORM OF PERINDOPRIL TERBUTILAMINE SALT, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| AR053147A1 (en) | CRYSTALINE FORM OF IVABRADINE CHLORHYDRATE, A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| AR066158A1 (en) | CRYSTALINE PIRIDAZINE COMPOSITE, A METHOD FOR THEIR ELABORATION AND A COMPOSITION THAT UNDERSTANDS IT. | |
| CL2011002255A1 (en) | Compounds derived from 2-acetamino-5-aryl- (1,2,4-triazolone or imidazolone), antagonist of the v1a and v2 receptor; pharmaceutical composition comprising them; preparation procedure; and its use in the treatment of heart failure, hypervolemic and euvolemic hyponatremia, ascites, in addition, among others. | |
| TW200736199A (en) | New crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| CL2004000918A1 (en) | COMPOUNDS DERIVED FROM QUINUCLIDINA, ANTAGONISTS OF THE M3 MUSCARINIC RECEIVER; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND TO TREAT AN ANTI-INFLAMMATORY OR ALLERGIC CONDITION, IN PARTICULAR OF THE RESPIRATORY ROADS | |
| TW200736198A (en) | New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| PE20030738A1 (en) | SUCCINIC ACID SALTS OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME | |
| NO20063516L (en) | New crystalline form III of agomelatine, process for its preparation and pharmaceutical compositions containing the | |
| FR2981933B1 (en) | OXOAZETIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN MEDICINE AND COSMETICS | |
| PE20131327A1 (en) | DELTA CRYSTAL FORM OF PERINDOPRYL ARGININE SALT, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
| AR029458A1 (en) | ACTIVE COMPOUNDS IN THE GLUCOCORTICOID RECEIVER | |
| UY26354A1 (en) | POLYMORPHIC SALT | |
| AU2015211518B2 (en) | Pharmaceutical composition including 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone and capsule formulation including the pharmaceutical composition | |
| PA8474401A1 (en) | 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN | |
| PE20070456A1 (en) | SALICILATE AND GENTIZATE OF THE COMPOUND 8- {4- [3- (5-FLUORO-1H-INDOL-3-IL) -PROPYL] -PIPERAZIN-1-IL} -2-METHYL-4H-BENZO [1,4] OXAZIN-3-ONA | |
| TH1901003346A (en) | Composition and method related to pyridinoylpiperidine 5-HT1F agonist | |
| GB0114699D0 (en) | Organic compounds |